Navigation Links
Silence Therapeutics' Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
Date:8/19/2010

ry of novel peptide-based biodegradable polycationic polymers for systemic siRNA administration.  Additionally, the company has a platform of novel siRNA molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules, including increased stability against nuclease degradation.  Silence's unique RNAi assets also include structural features for a next generation of RNAi molecules and additional proprietary siRNA sequences against more than 50 highly valued oncology and other disease targets.

The company's strong and diverse intellectual property portfolio includes exclusive licenses from the University of Massachusetts Medical School on three patent families associated with the Zamore "Design Rules," which cover broad structural features of siRNA design for more potent next generation siRNA sequences.

Silence Therapeutics is headquartered in London, UK, with research and development activities in Berlin and operations in Redwood City, CA.


'/>"/>
SOURCE Silence Therapeutics plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
2. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
3. Silence Therapeutics Appoints New Vice President of Research
4. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
5. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
6. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
7. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
8. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
9. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
10. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
11. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... LAWRENCEVILLE, N.J. , May 28, 2015 ... announced that it has received commitments from two institutional ... million of the Company,s common stock in an at-the-market ... warrants to purchase common stock. The Company ... pursuant to which the Company agreed to sell an ...
(Date:5/28/2015)... BioNorth Texas (BioNorthTX), an independent, non-profit ... sciences industry in northern region of Texas, held ... Foundry in Dallas on April 27, 2015. The ... broad spectrum of biotech professionals from the North ... in partnering with key life sciences organizations both ...
(Date:5/28/2015)... , May 28, 2015 Biscayne Pharmaceuticals, ... potential of its growth hormone-releasing hormone (GHRH) technology will ... 2015 ASCO Annual Meeting. The data show that the ... anti-cancer GHRH blockers, is present on many primary breast ... suggest that GHRH antagonists could have broad anti-cancer potential ...
(Date:5/28/2015)... The Fertility Centers of New England is ... has taken on a new and expanded role as ... guidance, leadership, oversight and quality assurance for the practice. ... our team of experienced reproductive endocrinologists,” said Fertility Centers ... M.D. “Her expertise and compassionate, individualized care have helped ...
Breaking Biology Technology:Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3BioNorthTX Holds Inaugural Board of Directors Meeting 2BioNorthTX Holds Inaugural Board of Directors Meeting 3Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3Danielle Vitiello, MD of Fertility Centers of New England, Named New Medical Director 2
... by Launch of Nine Emerging Therapies, Including Five Oral Agents, According ... ... Resources, WALTHAM, Mass., May 29 Decision Resources, one of the,world,s ... highly anticipated launch of the first,oral agents formally approved for multiple sclerosis ...
... Inc. (Nasdaq: MAPP ) today announced the appointment ... Vice President of Human,Resources., Mr. Rosa brings over ... recently, Mr. Rosa worked at Carl Zeiss Meditec, Inc. ... had held since May of,2002. He was an integral ...
... Incorporated,(Nasdaq: GPRO ) announced today that the Company ... specific molecular diagnostic test to detect,high-risk strains of the ... Assay has been CE marked and is currently available,for ... marking and launch of our APTIMA HPV Assay in ...
Cached Biology Technology:Oral Drug From Novartis/Mitsubishi Tanabe Will Capture the Largest Market Share of All Emerging Multiple Sclerosis Therapies in 2017 2MAP Pharmaceuticals Appoints Marco Rosa Vice President of Human Resources 2Gen-Probe Launches in Europe CE-Marked APTIMA(R) HPV Assay for Detection of Human Papillomavirus 2Gen-Probe Launches in Europe CE-Marked APTIMA(R) HPV Assay for Detection of Human Papillomavirus 3Gen-Probe Launches in Europe CE-Marked APTIMA(R) HPV Assay for Detection of Human Papillomavirus 4Gen-Probe Launches in Europe CE-Marked APTIMA(R) HPV Assay for Detection of Human Papillomavirus 5
(Date:5/18/2015)... May 18, 2015 Fingerprint Cards (FPC) ... FPC1025, FPC1145, FPC1155 and FPC1035 from one if its module ... and including Q3 2015 and the sensors will be used ... order values for 2015 hereby amount to 740 MSEK to ... of 140 MSEK and a number of smaller orders not ...
(Date:5/11/2015)... 2015 Curemark LLC, a privately held drug ... new Phase III double blind, randomized, placebo-controlled clinical trial ... on all children ages 3-8 with Autism. Previously, Curemark ... double blinded clinical trial for CM-AT in children ages ... digestive enzyme chymotrypsin. This new trial will help determine ...
(Date:5/5/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, reminds investors and media that  Mr. David ... CARTES SECURE CONNEXIONS AMERICA 2015, held in Washington ... three-day conference is organized into a series of nine session ... Global Fraud: Where is the Trust in Cyberspace? and ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... plants to treat their offspring for disease, research by biologists ... 6 in the journal Ecology Letters. "We ... plants, can reduce parasite infection in the monarchs," says Jaap ... "And we have also found that infected female butterflies prefer ...
... at the Gladstone Institute of Virology and Immunology (GIVI) have ... in the liver is required for the infectious activity of ... new strategy for treating the infection. More than 160 ... is available to prevent further spread of the disease. Current ...
... at the Georgia Institute of Technology and Emory University have ... material into the body to improve the treatment of inflammatory ... become a popular research area because of its potential therapeutic ... a living organism has been an obstacle. In the ...
Cached Biology News:Study finds monarch butterflies use medicinal plants to treat offspring for disease 2Gladstone scientists link hepatitis C virus infection to fat enzyme in liver cells 2Researchers develop oral delivery system to treat inflammatory bowel diseases 2Researchers develop oral delivery system to treat inflammatory bowel diseases 3
For mRNA Differential Display with three one-base anchored oligo-dT primers and rationally designed arbitrary 13mers. These kits feature the latest generation of isotopic mRNA Differential Display t...
Request Info...
... Panomer 9 oligodeoxynucleotides are ... labeled at the 5' ... Alexa Fluor dyes and ... assessing microarray spot morphology, ...
Topoisomerase I, isolated from wheat germ, is an enzyme capable of removing negative supercoils from covalently closed circular DNA (1)....
Biology Products: